Prescription medicine
Vonoprazan Brand names: Voquezna
Vonoprazan (Voquezna) is a prescription medicine with an FDA approval on record since 2023. No generic is listed; pharmacies paid $22.41 per Voquezna 20 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the vonoprazan FDA label on DailyMed (effective July 16, 2026, Phathom Pharmaceuticals Inc.); the NDA 215151 record on Drugs@FDA; every vonoprazan label on DailyMed.
Highlights of the record
FDA label of July 16, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageVOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.
Forms and strengths
- 13.36 mg
- 26.72 mg
Tablet.
On the market
- Earliest approval on file
- November 1, 2023 Voquezna, Phathom; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- August 11, 2030 Voquezna tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $22.41 per tablet Voquezna 20 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 7,359 through July 30, 2026
What is vonoprazan used for?
From the label: indications and usageVOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. […]
Conditions named in the indications of vonoprazan's FDA labels, with every medicine labeled for each:
Source: FDA drug label (VOQUEZNA), Phathom Pharmaceuticals Inc., effective July 16, 2026 (SPL set 0cc52ac5-77ec-4d66-a770-762a1a960914), via openFDA; the full label on DailyMed
Is there a generic for vonoprazan (Voquezna)?
No generic vonoprazan is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Voquezna tablets: the compound patent runs to April 10, 2030, and the last listed entry to August 11, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2023 earliest approval on file
- 2030 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for vonoprazan (Voquezna)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $22.41 per Voquezna 20 mg tablet, up 3% from $21.78 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Voquezna 10 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Voquezna 10 mg tablet | Brand | $22.40 per tablet | $671.90 | +3% |
| Voquezna 20 mg tablet | Brand | $22.41 per tablet | $672.36 | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the vonoprazan label say about other medicines?
The vonoprazan label names 14 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amoxicillin | contraindications | For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information. |
| Atazanavir | drug interactions | Atazanavir Avoid concomitant use with VOQUEZNA. |
| Cilostazol | drug interactions | CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol) Clinical Effect Vonoprazan is a CYP2C19 inhibitor [see Clinical Pharmacology (12.3) ]. |
| Citalopram | drug interactions | CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol) Clinical Effect Vonoprazan is a CYP2C19 inhibitor [see Clinical Pharmacology (12.3) ]. |
| Clarithromycin | contraindications | For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information. |
| Clopidogrel | drug interactions | CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol) Clinical Effect Vonoprazan is a CYP2C19 inhibitor [see Clinical Pharmacology (12.3) ]. |
| Dasatinib | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
| Digoxin | warnings and precautions | Consider monitoring magnesium and calcium levels in at-risk patients, or if there is concomitant use of digoxin or other drugs that cause hypomagnesemia. ( 5.7 ) Interactions with Investigations for Neuroendocrine Tumors: |
| Erlotinib | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
| Itraconazole | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
| Ketoconazole | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
| Mycophenolate mofetil | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
| Nelfinavir | drug interactions | Nelfinavir Other antiretrovirals See the prescribing information of other antiretroviral drugs dependent on gastric pH for absorption prior to concomitant use with VOQUEZNA. |
| Nilotinib | drug interactions | Other Drugs (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Effect Vonoprazan reduces intragastric acidity [see Clinical Pharmacology (12.2) ], which may decrease the absorption of drugs reducing their effectiveness. |
Source: FDA drug label (VOQUEZNA), Phathom Pharmaceuticals Inc., effective July 16, 2026 (SPL set 0cc52ac5-77ec-4d66-a770-762a1a960914), via openFDA; the full label on DailyMed
What do FAERS reports show for vonoprazan?
The FDA Adverse Event Reporting System holds 7,359 reports that list vonoprazan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,007 are coded as a death and 3,049 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (2,176, against a median of 166 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as vonoprazan?
21 other medicines are given the same way (oral) and in the same FDA class as vonoprazan or labeled mainly for the same use (acid reflux and ulcers), the same class first. Acid reflux and ulcers lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Calcium carbonate | Acid reflux and ulcers | none listed | $0.0315 per tablet 750 mg tablet chewable | No current entry |
| Omeprazole | Acid reflux and ulcers | 121 labelers | $0.0295 per capsule 20 mg capsule | A presentation being discontinued |
| Famotidine | Acid reflux and ulcers | 144 labelers | $0.0289 per tablet 20 mg tablet | No current entry |
| Esomeprazole | Acid reflux and ulcers | 117 labelers | $0.145 per capsule 20 mg capsule | No current entry |
| Pantoprazole | Acid reflux and ulcers | 52 labelers | $0.0358 per tablet 40 mg tablet | No current entry |
| Lansoprazole | Acid reflux and ulcers | 59 labelers | $0.106 per capsule 30 mg capsule | No current entry |
| Sucralfate | Acid reflux and ulcers | 43 labelers | $0.173 per tablet 1 g tablet | No current entry |
| Metoclopramide | Acid reflux and ulcers | 28 labelers | $0.0439 per tablet 10 mg tablet | No current entry |
Every medicine labeled for the same conditions as vonoprazan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to vonoprazan
- 21 medicines for the same use
- Vonoprazan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other